United Therapeutics
NYSE/NASDAQ:UTHRBiotechResearch Triangle Park, North Carolina, United States · Est. 1996 · 2,700 employees
United Therapeutics develops and commercializes innovative therapies for pulmonary hypertension, cystic fibrosis, and other life-threatening diseases.
3
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
9
Indications↗
Distinct diseases across all programs
81
Clinical Trials↗
All sponsored trials (all statuses)
25
Orange Book Patents
Across 2 drugs with upcoming expirations
Pipeline
Pipeline Snapshot
By Phase
3 drugs in development
Approved2
Phase 33
Phase 22
Preclinical1
By Therapeutic Area
top 2
Cardiovascular
350%
Respiratory
233%
R&D Momentum
40/100
Pipeline Velocity
11/100
Trial Completion Rate
58/100
Pipeline Concentration
39/100
Pipeline Freshness
37/100
Strategic Signals
- ↗Active in Respiratory but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Last 14 days
Jul 14, 2026
Recruiting
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
Jul 7, 2026
Terminated
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Ralinepag to Evaluate Safety and Effects on Exercise Capacity Assessed by CPET in Subjects With WHO Group 1 Pulmonary Hypertension Who Recently Initiated Therapy
Earlier
Mar 9, 2026EX-99.1UNITED THERAPEUTICS Corp (UTHR) (CIK 0001082554)
Mar 1, 2026TrialStudy to Evaluate the Safety and Efficacy of the GGTA1 KO Thymokidney in Patients With ESRD
Oct 29, 2025TrialStudy to Evaluate the Safety and Efficacy of the 10 GE Xenokidney in Patients With ESRD
May 23, 2025FDARemodulin — YUTREPIA
Sep 28, 2023FDARemodulin — REMODULIN
Oct 20, 2022TrialA Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension
4 more events
Oct 4, 2022TrialMultinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
Sep 6, 2022TrialExtension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease
May 23, 2022FDARemodulin — TYVASO DPI
Jun 1, 2021TrialStudy of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
Details
Company Info
Company Overview
$14.5B
Mkt Cap
$1.6B
Revenue
$1.7B
Cash
CEOMartine Rothblatt
Founded1996
Employees2,700
HQResearch Triangle Park, North Carolina, United States
ExchangeNYSE/NASDAQ:UTHR
Websiteunitedhealthcare.com
LinkedInCompany Page
Therapeutic Focus
CardiovascularMusculoskeletalInfectious DiseaseOncologyOtherRespiratoryNephrologyImmunologyMetabolic & Endocrine
Recent SEC Filings
EX-99.1Mar 9, 2026
UNITED THERAPEUTICS Corp (UTHR) (CIK 0001082554)
Pipeline
Drug Pipeline
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Cardiovascular
Respiratory
Unknown / Other
Cardiovascular
Respiratory
Unknown / Other
Regulatory
Regulatory Timeline
20091 event
FDAJul 30
Remodulin — TYVASO
Application NDA022387 (NDA)
20131 event
FDADec 20
Orenitram — ORENITRAM
Application NDA203496 (NDA)
20151 event
FDAMar 10
Unituxin — UNITUXIN
Application BLA125516 (BLA)
20181 event
FDAJul 30
Remodulin — REMODULIN
Application NDA208276 (NDA)
20221 event
FDAMay 23
Remodulin — TYVASO DPI
Application NDA214324 (NDA)
20231 event
FDASep 28
Remodulin — REMODULIN
Application NDA021272 (NDA)
20251 event
FDAMay 23
Remodulin — YUTREPIA
Application NDA213005 (NDA)
20261 event
SECMar 9
UNITED THERAPEUTICS Corp (UTHR) (CIK 0001082554)
Accession: 000-26301
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)